Zonin Bets On Chile With New Dos Almas BrandJuly 6, 2017
Known for its broad portfolio of Italian wines—including Zonin Prosecco and Moscato-led Castello del Poggio—Zonin USA is now foraying into the Chile category with a new range called Dos Almas.The brand name translates as “Two Souls,” and refers to the label’s concept of combining Italian winemaking with Chilean terroir.
A partnership with Chile’s Vial family of Viña Ventisquero, Dos Almas will roll out in the U.S. starting early next year. Zonin export marketing manager David Fioravanti tells SND that the company found kindred souls in the Vials, whose vineyard holdings across the Leyda, Casablanca, Colchagua and Maipo areas mirror Zonin’s multi-regional presence in Italy.
The Dos Almas lineup will retail at $12-$14 and include a Gran Reserva Cabernet Sauvignon and Carmenere from Colchagua; a Red Blend from Maipo; and a Pinot Noir, Sauvignon Blanc and Brut sparkling wine from Casablanca. Production for the inaugural year is 200,000 bottles, and the company is targeting about 700,000 bottles annually within three years.
Fioravanti sees particular potential for the Charmat-method Dos Almas Brut, which is 80% Chardonnay and 20% Moscatel, given Zonin’s expertise in sparkling wines and U.S. consumers’ burgeoning interest in the category. “With Dos Almas Brut, we wanted to create something a little different that would not compete with our Italian sparkling wines, and we think this fits the bill,” Fioravanti says. Looking ahead to 2018, Zonin plans to add an Apalta-sourced icon wine to the Dos Almas range. That offering is intended to create a halo for the brand, Fioravanti adds, noting that Apalta remains an exclusive appellation for fine wines, boosted by big-name producers like Lapostolle and Montes.
In related news, Zonin has introduced new packaging on its flagship Prosecco. Fioravanti says the move is aimed at putting greater emphasis on the brand name on Zonin’s bottles to create better recognition among consumers. An Impact “Hot Brand,” Zonin Prosecco grew 18% to 419,000 cases in the U.S. market last year. —Daniel Marsteller